Table 1 Crude and adjusted prevalencea of HCV testing, positivity, cured or cleared, and last RNA positive waiting for treatment, according to sex
| Â | General population | Diabetic population | AS patients | |||
|---|---|---|---|---|---|---|
Crude (95%CI) | Adjusted (95%CI) | Crude (95%CI) | Adjusted (95%CI) | Crude (95%CI) | Adjusted (95%CI) | |
HCV tested | ||||||
 Female | 148.7 (147.2–150.1) | 152.4 (151.1–153.7) | 143.8 (137.8–150.1) | 179.1 (164.7–193.6) | 555.6 (490.1–626.6) | 451.4 (390.3–512.5) |
 Male | 79.8 (79.7–80.9) | 78.4 (77.3–79.4) | 132.7 (127.4–138.2) | 122.9 (109.0–136.8) | 461.1 (433.5–490.0) | 367.8 (336.9–398.8) |
HCV positive | ||||||
 Female | 6.0 (5.7–6.3) | 5.4 (5.1–5.7) | 12.5 (10.7–14.4) | 8.2 (6.2–10.3) | 184.5 (148.0–227.3) | 123.8 (96.4–151.2) |
 Male | 7.0 (6.7–7.3) | 6.6 (6.3–6.9) | 12.6 (11.0–14.4) | 10.8 (8.6–13.1) | 163.6 (147.3–181.2) | 113.0 (99.8–126.2) |
Cured or cleared | ||||||
 Female | 677.5 (629.3–728.4) | 692.2 (644.5–739.9) | 644.1 (507.5–806.1) | 337.1 | 571.4 (390.9–807.7) | 458.4 |
 Male | 735.8 (689.3–784.6) | 746.2 (716.1–776.3) | 756.0 (630.2–899.4) | 526.4 | 726.7 (625.9–838.8) | 432.5 |
Last RNA+ waiting for treatment | ||||||
 Female | 317.0 (284.3–352.4) | 304.0 (256.3–351.6) | 347.5 (249.3–471.4) | 191.1 | 392.9 (246.2–594.8) | 176.2 |
 Male | 246.8 (220.0–275.8) | 234.5 (204.8–264.1) | 220.2 (155.1–303.6) | 121.2 | 230.5 (175.4–297.3) | 295.3 |